MannKind Corp
MNKD5.250USD
-0.170-3.14%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.61BMarket Cap
55.14P/E TTM
More Details of MannKind Corp Company
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
MannKind Corp Info
Ticker SymbolMNKD
Company nameMannKind Corp
IPO dateJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Number of employees407
Security typeOrdinary Share
Fiscal year-endJul 28
Address1 Casper Street
CityDANBURY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code06810
Phone18186615000
Websitehttps://mannkindcorp.com/
Ticker SymbolMNKD
IPO dateJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Company Executives of MannKind Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
By RegionUSD
Name
Revenue
Proportion
United States
76.53M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Other
78.34%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Other
78.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.00%
Investment Advisor/Hedge Fund
17.68%
Hedge Fund
10.68%
Research Firm
3.31%
Individual Investor
1.72%
Bank and Trust
0.62%
Pension Fund
0.32%
Venture Capital
0.03%
Insurance Company
0.03%
Other
42.62%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
473
171.20M
55.75%
-15.78M
2025Q2
477
184.37M
60.10%
+2.23M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
23.58M
7.69%
+2.13M
+9.93%
Jun 30, 2025
The Vanguard Group, Inc.
18.10M
5.9%
+838.68K
+4.86%
Jun 30, 2025
State Street Investment Management (US)
10.75M
3.5%
+1.28M
+13.47%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.62M
2.48%
+831.48K
+12.25%
Jun 30, 2025
Nitorum Capital, L.P.
7.01M
2.29%
-774.19K
-9.94%
Jun 30, 2025
Two Sigma Investments, LP
5.91M
1.93%
-1.19M
-16.80%
Jun 30, 2025
Avoro Capital Advisors LLC
5.85M
1.91%
-2.90M
-33.14%
Jun 30, 2025
Millennium Management LLC
4.48M
1.46%
-1.34M
-23.03%
Jun 30, 2025
Qube Research & Technologies Ltd
4.07M
1.33%
+825.61K
+25.48%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.05M
1.32%
+528.66K
+15.00%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Biotechnology & Genome ETF
3.53%
ALPS Medical Breakthroughs ETF
1.01%
Invesco NASDAQ Future Gen 200 ETF
0.57%
VictoryShares Small Cap Free Cash Flow ETF
0.43%
Global X Aging Population ETF
0.31%
SPDR S&P Biotech ETF
0.29%
SPDR S&P Kensho New Economies Composite ETF
0.26%
Timothy Plan US Small Cap Core ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
View more
Invesco Biotechnology & Genome ETF
Proportion3.53%
ALPS Medical Breakthroughs ETF
Proportion1.01%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.57%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.43%
Global X Aging Population ETF
Proportion0.31%
SPDR S&P Biotech ETF
Proportion0.29%
SPDR S&P Kensho New Economies Composite ETF
Proportion0.26%
Timothy Plan US Small Cap Core ETF
Proportion0.22%
ProShares Ultra Nasdaq Biotechnology
Proportion0.17%
Invesco Nasdaq Biotechnology ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
